Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

Background This trial evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics, and activity of volasertib, a selective Polo-like kinase 1 inhibitor that induces mitotic arrest and apoptosis, combined with cisplatin or carboplatin in patients with advanced/metastatic solid tumors (NCT009...

Descripción completa

Detalles Bibliográficos
Autores principales: Awada, Ahmad, Dumez, Herlinde, Aftimos, Philippe G., Costermans, Jo, Bartholomeus, Sylvie, Forceville, Kathleen, Berghmans, Thierry, Meeus, Marie-Anne, Cescutti, Jessica, Munzert, Gerd, Pilz, Korinna, Liu, Dan, Schöffski, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435638/
https://www.ncbi.nlm.nih.gov/pubmed/25794535
http://dx.doi.org/10.1007/s10637-015-0223-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435638/
https://www.ncbi.nlm.nih.gov/pubmed/25794535
http://dx.doi.org/10.1007/s10637-015-0223-9

Ejemplares similares